Upcoming Live Webinar and Q&A Session with Dr Brian D. Adams of Harvard Medical School and sponsorde by Abcam:
“MicroRNAs as biomarkers and therapeutic targets in triple negative breast cancer”
January 21, 2016 | 11:00am EST/ 8:00am PST
Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity because of its aggressive behavior, increased incidence in younger women, and lack of effective targeted therapies. miRNAs could serve as superior therapeutic agents for this breast cancer type.
This webinar will review:
- miRNAs and noncoding RNA biology
- Dysregulation of miRNAs associates with disease etiology
- miRNAs as biomarkers
- Techniques used to profile and study miRNA biology
- miRNAs as therapeutic agents and/or targets
Can’t attend the live webinar? Don’t worry! Simply register today and receive the on-demand recording in your inbox within 24 hours of the live event.
About the Speaker:
Brian D. Adams is currently an Instructor at Harvard Medical School in the lab of Dr Frank Slack with over 9 years of experience in the fields of microRNA and cancer research. Brian completed his graduate studies at the University of Connecticut, where he was the first to identify that miRNAs are a crucial regulator of hormone-responsiveness in breast cancer patients. He further completed his postdoctoral studies at Yale, where he investigated how miRNAs can serve as chemo-sensitizers in the context of normal hematopoietic recovery and acute myeloid leukemia.
Incoming search terms for this article:
LA JOLLA, Calif., Oct. 28, 2015 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies’ research collaboration to identify microRNAs as biomarkers for multiple sclerosis (“MS”). To earn the milestone, Regulus’ microMarkersSM division used its robust technology platform and bioinformatics expertise to analyze the treatment effects of a Biogen relapsing MS drug on circulating microRNA profiles previously identified by Regulus.
“Our partnership with Biogen is one example of how Regulus microMarkersSM is researching the role and potential of microRNAs as biomarkers for numerous diseases. We’re excited to have identified a promising microRNA biomarker for MS, which we believe was a critical step to understand how microRNAs may change response to drug treatment,” said Paul Grint, M.D., President and [click to continue…]
MicroRNAs have emerged as promising biomarkers of organ damage including injury of the liver. In this study the new generation of high-throughput sequencing technology was applied to detect circulating miRNAs in serum from patients with accidental acetaminophen overdose and identified a set of 33 known miRNAs and 3 novel miRNA-like small RNAs that are functionally associated with liver-specific biological processes and relevant to acetaminophen toxic mechanisms. The study suggests a profile of circulating miRNAs in human serum that might provide additional biomarker candidates for drug-induced liver injury and possibly adds mechanistic information relevant to liver injury.
Figure: Serum levels of liver-associated miRNAs after acetaminophen overdose. The liver associated miRNAs miR-122 and miR-192 were detected in serum from acetaminophen-overdosed patients. The graph represents serum levels, based on normalized sequencing reads, of the liver-associated miRNA hsa-miR-122 (A) and hsa-miR-192 (B) in control and acetaminophen-overdosed samples.
For the full article:
Krauskopf J, Caiment F, Claessen SM, Johnson KJ, Warner RL, Schomaker SJ, Burt DA, Aubrecht J, Kleinjans JC. Application of High-Throughput Sequencing to Circulating microRNAs Reveals Novel Biomarkers for Drug-induced Liver Injury. Toxicol Sci. 2014 Oct 29. pii: kfu232. [Epub ahead of print] PubMed PMID: 25359176.
MONMOUTH JUNCTION, NJ–(Marketwired – January 02, 2014) – DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled “Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study” in Aging. Mild Cognitive Impairment is a condition characteristic of early stages of many neurodegenerative diseases, including Alzheimer’s disease. The article can be accessed online at http://www.impactaging.com/papers/v5/n12/abs/100624a.html.
DiamiR reported that two families of microRNA biomarkers, miR-132 and miR-134 families, detect Mild Cognitive Impairment with the overall accuracy of 96 percent and 87 percent respectively, when plasma samples of Mild Cognitive Impairment patients are compared to plasma samples of age/gender matched control subjects. The two families of biomarkers were identified among neurite/synapse enriched microRNAs and paired with brain-enriched microRNA normalizers using proprietary algorithms and software developed at DiamiR. The biomarkers are believed to reflect pathological [click to continue…]
EVRY, France–(BUSINESS WIRE)–
IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in oncology and autism, announced today that it has finalized an agreement providing the company with exclusive licensing rights for the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be a predictor of progression free survival in patients with metastatic colorectal cancer treated with anti-EGFR therapy. This exclusive license is based on original research led by Professor Laurent-Puig, M.D., Ph.D., Professor, Department of Genetics and head of the Clinical Oncogenetic Unit at European Georges Pompidou Hospital University Paris Descartes in Paris, France. IntegraGen obtained the exclusive license for the worldwide rights for this biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique – Hopitaux de Paris, all leading French academic institutions which, along with IntegraGen, are co-owners of the patent.
“This agreement increases IntegraGen’s proprietary oncology biomarker portfolio and enhances our ability to offer new molecular diagnostic tests to physicians which can assist their clinical management of cancer patients,” stated Dr. Bernard Courtieu, IntegraGen’s CEO. “This agreement, which is a direct result of IntegraGen’s collaborative research with Prof. Laurent-Puig and his research team, will [click to continue…]